Advertisement

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
00:00
00:00
00:00
 

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

2022 ASCO Annual Meeting

Advertisement

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The prognosis for patients with poorly differentiated neuroendocrine carcinoma, which is extrapulmonary is poor. Most of these patients present with advanced disease and their prognosis is usually less than a year. The treatment for these patients is predominantly like small cell lung cancer or lung neuroendocrine carcinoma. With these patients with extra pulmonary neuroendocrine carcinoma, they have an aggressive histology with a KI67, by definition being greater than 20%. The treatment in the first line advanced setting has been a platinum based treatment for the last 30 years and there's no standard treatment for a second line, and this is an area of unmet need. And therefore the NET-02 trial addresses this unmet need. In the NET-O2 trial, one of the treatment arms is liposomal irinotecan 5-fluorouracil folinic acid. This has been found and has been reported to increase intratumoral levels of irinotecan and SN-38, which is the active metabolite of irinotecan. The second arm in NET-02 trial is docetaxel, which has been used as a standard of care option in small cell lung carcinoma as per the NCCN guidelines. The key eligibility for this study was that patients should have extrapulmonary neuroendocrine carcinoma grade 3. With a KI67 of greater than 20% have received previous platinum based treatment and have an equal performance status of less than or equal to two. The primary endpoint for this study was six month PFS rate, with secondary endpoints being response rate, PFS, overall survival, toxicity, quality of life and translational endpoints. The quality of life and translational endpoint results will be presented at a later date. So patients had scans every eight weeks and continued on treatment until progressive disease or intolerable toxicity. The statistical design was allowing for a 5% dropout rate. There was an 80% power to detect the one-sided 95% confidence interval for the six month PFS rate and excluding 15% with the true rate being greater than 30%. So if a patient had a six month PFS rate of 30% or greater, that was the required level of efficacy, and a rate of 15% or less give grounds for rejection. These rates were based on review of retrospective data where the six month PFS rate was reported and ranged from 15% to 25%. So at a median follow up of 8.1 months, the six month PFS rate was, primary endpoint was met by liposomal irinotecan 5-fluorouracil with the six month PFS rate of being 31% with a 95% lower confidence limit of 17.25% and exceeding the rate of 15%, which was gave grounds for rejection. For docetaxel, the six month PFS rate was 13.8%, with a lower confidence limit of 4.85%. The median PFS for liposomal irinotecan was three months versus two for docetaxel. Median overall survival was nine months versus five for docetaxel. And the response rate was similar in both arms 10.3%. So in conclusion, the primary end point of six month PFS rate was met by liposomal irinotecan 5-fluorouracil folinic acid, but not docetaxel, exceeding the required threshold for efficacy. And the response rate was similar in both arms. The median overall survival was greater in the liposomal irinotecan arm, with the median overall survival of nine months versus five months with the docetaxel. The adverse events, the toxicity was similar with no new safety signals and based on these results, liposomal irinotecan warrants further exploration in these patients with extrapulmonary, poorly differentiated neuroendocrine carcinoma. And it would be important that guidelines would be developed using trial based evidence for these patients.

Related Videos

Lung Cancer
Genomics/Genetics

Gilberto de Lima Lopes, Jr, MD, MBA, and Matthew Krebs, PhD, on NSCLC: Updated Results With Amivantamab-vmjw

Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Matthew Krebs, PhD, of The University of Manchester and The Christie NHS Foundation Trust, discuss results from the CHRYSALIS study. The trial showed that the bispecific antibody amivantamab-vmjw demonstrated antitumor activity, even after prior treatment, in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation (Abstract 9008).

Sarcoma

Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide

Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).

Supportive Care
Symptom Management

Sriram Yennu, MD, on Cancer-Related Fatigue: Is Open-Labeled Placebo an Effective Treatment?

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses the placebo response in patients with advanced cancer and cancer-related fatigue. His latest findings show that open-labeled placebo was efficacious in reducing cancer-related fatigue and improving quality of life in fatigued patients with advanced cancer at the end of 1 week. The improvement in fatigue was maintained for 4 weeks (Abstract 12006).

Head and Neck Cancer

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).

 

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).

Advertisement

Advertisement




Advertisement